

Jeffrey M Gelfand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4847516/publications.pdf>

Version: 2024-02-01

91
papers

8,525
citations

125106

35
h-index

71088

80
g-index

92
all docs

92
docs citations

92
times ranked

11325
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying falls remotely in people with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1889-1898.	1.8	5
2	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	2.8	39
3	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	13
4	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive <sc>MS</sc>". <i>Annals of Neurology</i> , 2022, 91, 735-736.	2.8	0
5	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	0.9	5
6	Transitioning From S1P Receptor Modulators to B Cell"Depleting Therapies in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	7
7	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 972-977.	0.9	7
8	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1432-1441.	1.4	9
9	Retinal <sc>INL</sc> Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. <i>Annals of Neurology</i> , 2021, 89, 192-193.	2.8	14
10	Effects of COVID-19 "Sheltering in Place" on Activity in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, e216-e218.	0.8	8
11	CoachMS, an innovative closed-loop, interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732198893.	0.5	4
12	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. <i>Neurology: Clinical Practice</i> , 2021, 11, 352-357.	0.8	1
13	Underutilization of physical therapy for symptomatic women with MS during and following pregnancy. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102703.	0.9	4
14	Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 804-804.	0.9	1
15	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
16	Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2021, 78, 1355.	4.5	14
17	<sc>ANA</sc> Investigates Therapeutic Advancements in Neuroimmunology. <i>Annals of Neurology</i> , 2021, 90, 720-721.	2.8	0
18	Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120004.	0.3	10

#	ARTICLE	IF	CITATIONS
19	Foundational Telemedicine Workshop for First-Year Medical Students Developed During a Pandemic. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2021, 17, 11171.	0.5	9
20	Neurosarcoidosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	80
21	Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. Brain, 2020, 143, 503-511.	3.7	38
22	Gut microbiotaâ€“specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. Science Immunology, 2020, 5, .	5.6	132
23	Imaging correlates of visual function in multiple sclerosis. PLoS ONE, 2020, 15, e0235615.	1.1	5
24	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22932-22943.	3.3	119
25	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	1.2	14
26	Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment. JAMA Neurology, 2020, 77, 933.	4.5	0
27	Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 343-353.	1.4	16
28	Exploratory analysis of the potential for advanced diagnostic testing to reduce healthcare expenditures of patients hospitalized with meningitis or encephalitis. PLoS ONE, 2020, 15, e0226895.	1.1	10
29	Intrathecal B-cell activation in LGI1 antibody encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	24
30	A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development. Journal of Medical Internet Research, 2020, 22, e15605.	2.1	23
31	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
32	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
33	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
34	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
35	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1526-1534.	1.4	49
36	Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis. Neurology, 2019, 93, e433-e444.	1.5	13

#	ARTICLE	IF	CITATIONS
37	Progressive Neurological Impairment and an Enhancing Brainstem Lesion in a Middle-aged Man. JAMA Neurology, 2019, 76, 1397.	4.5	0
38	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e533.	3.1	18
39	Multiple sclerosis and sarcoidosis. Neurology: Clinical Practice, 2019, 9, 218-227.	0.8	12
40	Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. New England Journal of Medicine, 2019, 380, 2327-2340.	13.9	644
41	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. JAMA Network Open, 2019, 2, e190570.	2.8	69
42	Silent progression in disease activity-free relapsing multiple sclerosis. Annals of Neurology, 2019, 85, 653-666.	2.8	265
43	GABA _A receptor autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e552.	3.1	42
44	Validation of a consumer-grade activity monitor for continuous daily activity monitoring in individuals with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988866.	0.5	15
45	Harnessing electronic medical records to advance research on multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 408-418.	1.4	21
46	Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing. JAMA Neurology, 2018, 75, 947.	4.5	214
47	Sleep disturbance and symptom burden in sarcoidosis. Respiratory Medicine, 2018, 144, S35-S40.	1.3	11
48	Pleocytosis is not fully responsible for low CSF glucose in meningitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e425.	3.1	15
49	Migraine is common in patients with sarcoidosis. Cephalalgia, 2018, 38, 2079-2082.	1.8	5
50	Rituximab before and during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e453.	3.1	159
51	Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment. Annals of Neurology, 2018, 83, 730-738.	2.8	52
52	Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e505.	3.1	35
53	A young man with numbness in arms and legs. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e509.	3.1	1
54	Autoimmune encephalitis after herpes simplex encephalitis: insights into pathogenesis. Lancet Neurology, The, 2018, 17, 733-735.	4.9	30

#	ARTICLE	IF	CITATIONS
55	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. <i>JAMA Neurology</i> , 2018, 75, 1546.	4.5	247
56	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.5	154
57	Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	147
58	Focal cerebral β -amyloid angiopathy. <i>Neurology: Clinical Practice</i> , 2017, 7, 444-448.	0.8	2
59	Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. <i>Neurobiology of Aging</i> , 2017, 51, 141-147.	1.5	44
60	Risk of Multiple Sclerosis After a Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2017, 74, 262.	4.5	2
61	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. <i>Lancet, The</i> , 2017, 390, 2481-2489.	6.3	377
62	Infliximab for the treatment of CNS sarcoidosis. <i>Neurology</i> , 2017, 89, 2092-2100.	1.5	151
63	Demystifying Neurosarcoidosis and Informing Prognosis. <i>JAMA Neurology</i> , 2017, 74, 1296.	4.5	7
64	Clinical and Biological Insights from the University of California San Francisco Prospective and Longitudinal Cohort. <i>Lung</i> , 2017, 195, 553-561.	1.4	10
65	Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. <i>Journal of the Neurological Sciences</i> , 2017, 381, 83-87.	0.3	11
66	Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0154335.	1.1	156
67	Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. <i>Journal of Neurology</i> , 2016, 263, 1323-1331.	1.8	112
68	The severe side of the I γ G4-related hypertrophic pachymeningitis disease spectrum. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e197.	3.1	7
69	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	2.8	331
70	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology, The</i> , 2016, 15, 391-404.	4.9	2,782
71	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 897.	4.5	78
72	Diagnosing <i>Balamuthia mandrillaris</i> encephalitis with metagenomic Deep Sequencing. <i>Annals of Neurology</i> , 2015, 78, 722-730.	2.8	117

#	ARTICLE	IF	CITATIONS
73	Diagnosing Encephalitis, Not Otherwise Specified—Reply. <i>JAMA Neurology</i> , 2015, 72, 726.	4.5	0
74	Encephalitis of Unclear Origin Diagnosed by Brain Biopsy. <i>JAMA Neurology</i> , 2015, 72, 66.	4.5	26
75	Therapeutic Management of Severe Relapses in Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2015, 17, 345.	0.7	28
76	One Brain, Two Specialties, Converging Mechanisms: Neuronal Autoantibodies as a Rare Cause of Postpartum Psychosis. <i>American Journal of Psychiatry</i> , 2015, 172, 824-826.	4.0	1
77	Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e34.	3.1	61
78	Episodic Bradycardia as Neurocardiac Prodrome to Voltage-Gated Potassium Channel Complex/Leucine-Rich, Glioma Inactivated 1 Antibody Encephalitis. <i>JAMA Neurology</i> , 2014, 71, 1300.	4.5	51
79	Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy. <i>JAMA Neurology</i> , 2014, 71, 896.	4.5	102
80	Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTL. <i>Journal of Experimental Medicine</i> , 2014, 211, 1937-1945.	4.2	94
81	Precision medicine in chronic disease management: The multiple sclerosis screen. <i>Annals of Neurology</i> , 2014, 76, 633-642.	2.8	53
82	Multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 269-290.	1.0	98
83	Migraine and multiple sclerosis: Epidemiology and approach to treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 73-79.	0.9	22
84	Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 629.	4.5	107
85	Microcystic macular oedema in multiple sclerosis is associated with disease severity. <i>Brain</i> , 2012, 135, 1786-1793.	3.7	300
86	Color vision is strongly associated with retinal thinning in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 991-999.	1.4	64
87	Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. <i>Lancet Neurology</i> , The, 2012, 11, 963-972.	4.9	267
88	Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes. <i>PLoS ONE</i> , 2012, 7, e36847.	1.1	94
89	Heterogeneous patterns of tissue injury in NARP syndrome. <i>Journal of Neurology</i> , 2011, 258, 440-448.	1.8	48
90	Speech-activated myoclonus masquerading as stuttering. <i>Neurology</i> , 2009, 72, 1964-1964.	1.5	2

#	ARTICLE	IF	CITATIONS
91	Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4